-
Genomic testing found to change chemotherapy treatment decisions
A study has shown that after receiving Oncotype DX Recurrence Score results, physicians changed their chemotherapy recommendation in 30% of invasive, estrogen-receptor-positive, early-stage breast cancer patients with no lymph node involvement.